[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systemic-lupus-erythematosus-nephritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systemic-lupus-erythematosus-nephritis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100565455","monitoring-lupus-nephritis-through-urinary-extracellular-vesicles-100565455",false,"NCT06642402","Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles","Monitoring and Detecting Lupus Nephritis Through Urinary Extracellular Vesicles in Urine","SLE patients with kidney involvement\n\nInclusion criteria:\n\n* \\> 18 years old\n* Fulfilling the 2019 EULAR\u002FACR classification criteria\n* Positive autoantibodies, medical history and obejctive examination compatible with SLE\n* Referred to kidney biopsy\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nSLE patients with no sign of kidney disease\n\nInclusion criteria:\n\n* \\> 18 years old\n* Fulfilling the 2019 EULAR\u002FACR classification criteria\n* Positive autoantibodies, medical history and obejctive examination compatible with SLE\n* Normal plasma creatinine\n* Urine albumine\u002Fcreatinine \\\u003C 100 mg\u002Fg\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nHealthy controls:\n\nInclusion criteria:\n\n* \\> 18 years old\n* No known kidney disease\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Urine albumin-creatinine ratio \\> 100 mg\u002Fg or proteinuria \\> 100 mg\u002Fday\n* Postive autoantibodies\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nBiopsy control:\n\nInclusion criteria:\n\n* \\> 18 years old\n* Negative autoantibiodies and immunoglobulines\n* Referred to kidney biopsy\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome",true,"ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","1 Year","OBSERVATIONAL","Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.",[26],"Systemic Lupus Erythematosus Nephritis",[28,29,30,31],"Systemic Lupus Erythoematosus nephritis","Lupus nephritis","complement activation","kidney biopsy","RECRUITING","2025-09-02",{"date":35,"type":36},"2025-09-09","ACTUAL",{"date":38,"type":36},"2024-11-15",{"date":40,"type":21},"2030-05-01",{"name":42,"class":43},"Kolding Sygehus","OTHER",4]